Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression
|ClinicalTrials.gov Identifier: NCT00356304|
Recruitment Status : Completed
First Posted : July 25, 2006
Results First Posted : May 8, 2014
Last Update Posted : May 8, 2014
|Condition or disease||Intervention/treatment||Phase|
|Depression||Behavioral: Motivational interviewing Behavioral: Treatment as usual||Phase 1|
Depression is a serious mental illness characterized by symptoms that can interfere with a person's ability to work, study, eat, sleep, and enjoy activities that were once pleasurable. Studies have shown that people of Hispanic descent tend to underutilize mental health care services. Additionally, Hispanics have demonstrated lower compliance and completion rates for antidepressant treatment. This may be due to low socioeconomic status, lack of family financial support, and inadequate communication with mental health care providers. Motivational interviewing is a goal-oriented type of therapy that focuses on eliciting behavior change by identifying and mobilizing a person's values. This study will determine the effectiveness of culturally sensitive motivational interviewing in improving antidepressant medication adherence in Hispanics.
Participants in this 6-month, open-label study will be randomly assigned to receive either motivational interviewing in addition to their antidepressant therapy or treatment as usual. All participants will first attend a 45-minute screening visit, which will include questionnaires and an interview about psychiatric symptoms, medication attitudes, and medication adherence behavior. Participants will also receive an electronic medication container that will record how consistently medication is taken. Participants assigned to motivational interviewing will then attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. The group assigned to treatment as usual will not partake in motivational interviewing, but will continue to receive their normal care. All participants will return to the study site for follow-up assessments, which will include measures of antidepressant adherence, at Months 2 and 5.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Antidepressant Adherence Among Hispanics: A Motivational Interviewing Approach|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
Participants will receive motivational interviewing in addition to their antidepressant therapy
Behavioral: Motivational interviewing
Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
Active Comparator: 2
Participants will receive treatment as usual
Behavioral: Treatment as usual
Participants will continue with their normal treatment regimen as usual.
- Medication Adherence, as Measured by Electronic Pill Container [ Time Frame: Measured immediately post-treatment and at Months 2 and 5 months follow-ups ]Medication container caps (MEMS) recorded each instance where the antidepressant medication container was opened. An adherence index was derived the represented the percentage of days, within the medication period, where the container was opened.
- Treatment Retention [ Time Frame: Measured at Month 5 ]
- Beck Depression Inventory-II (BDI-II) [ Time Frame: Measured at Month 5 ]
The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3.
0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29-63: severe depression. Higher total scores indicate more severe depressive symptoms.
- Medication Attitudes [ Time Frame: Measured at Month 5 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356304
|United States, New Jersey|
|University Behavioral Healthcare|
|New Brunswick, New Jersey, United States, 08901|
|Principal Investigator:||Alejandro Interian, PhD||Rutgers, The State University of New Jersey|